吉西他滨联合高能聚焦超声治疗晚期胰腺癌效果的Meta分析

资力; 陈凯; 刘广林; 李仁礼; 许威

doi:10.3969/j.issn.1001-5256.2020.01.034

吉西他滨联合高能聚焦超声治疗晚期胰腺癌效果的Meta分析

DOI: 10.3969/j.issn.1001-5256.2020.01.034

1. 武警特色医学中心消化疾病研究所
2. 武警后勤学院
3. 天津市肝脏胰腺纤维化与分子诊疗重点实验室

基金项目:

天津市自然科学基金(17JCYBJC26700)；天津市科技计划项目(课题)(15ZXLCSY00040)；

详细信息

中图分类号: R735.9
计量
- 文章访问数: 1240
- HTML全文浏览量: 40
- PDF下载量: 201
- 被引次数: 0
出版历程
- 收稿日期: 2019-07-12
- 出版日期: 2020-01-20

Clinical effect of gemcitabine combined with high-intensity focused ultrasound in treatment of advanced pancreatic cancer: A Meta-analysis

Institute of Digestive Diseases,Characteristic Medical Ceter of Chinese People's Armed Police

Research funding:

摘要

摘要: 目的评价吉西他滨(Gem)联合高能聚焦超声(HIFU)治疗晚期胰腺癌的安全性和有效性。方法网上检索SCI、Cochrane数据库、Embase、Pubmed、万方数据、中国知网、CBM、VIP文献库,再辅助以扩展检索,将检索到的HIFU联合Gem治疗晚期胰腺癌的随机对照试验按照纳入标准筛选。采用Review Manager5. 3进行Meta评价。非异质性数据使用固定效应模型;异质性按照干预方法进行亚组分析来解释异质性;如果仍然不能用亚组分析来解释,则采用随机效应模型。使用相对危险度(RR)及其95%可信区间(95%CI)作为评估指标,选取纳入研究数目多的结果绘制漏斗图。结果共纳入8篇随机对照试验(474例患者),试验组与对照组都接受Gem为基础的化疗,试验组加用HIFU治疗。试验组与对照组3、6、12个月的生存率RR值分别为1. 07(95%CI:1. 00～1. 14)、2. 19(95%CI:1. 75～2. 75)和2. 35(95%CI:1. 07～5. 14)(P值均<0. 05);肿瘤控制效果RR为1. 64(95%CI:1. 21～2. 24)(P=0. 002)...
- 胰腺肿瘤 /
- 高强聚焦超声消融 /
- 吉西他滨 /
- Meta分析(主题)
Abstract: Objective To evaluate the clinical effect and safety of high-intensity focused ultrasound(HIFU) combined with gemcitabine in the treatment of advanced pancreatic cancer. Methods SCI,Cochrane Library,Embase,PubMed,Wanfang Data,CNKI,CBM,and VIP were searched for randomized controlled trials(RCTs) of HIFU combined with gemcitabine in the treatment of advanced pancreatic cancer,with the assistance of expanded search,and these RCTs were screened according to the inclusion criteria. Review Manager 5. 3 was used to perform the Meta-analysis. A fixed effects model was used for non-heterogeneous data; heterogeneity was explained by subgroup analysis based on intervention methods,and if it could not be explained by subgroup analysis,a random effects model was used. Relative risk(RR) and 95% confidence interval(CI) were used as evaluation indices,and funnel plots were generated based on the outcome measure involved in the highest number of studies. Results A total of 8 RCTs with 474 patients were included. The patients in the experimental group received gemcitabine-based chemotherapy and HIFU,and those in the control group received gemcitabine-based chemotherapy alone. Compared with the control group,the experimental group had significantly better results in 3-,6-,and 12-month survival rates(3-month: RR = 1. 07,95% CI: 1. 00-1. 14,P < 0. 05; 6-month: RR = 2. 19,95% CI: 1. 75-2. 75,P < 0. 05; 12-month: RR =2. 35,95% CI: 1. 07-5. 14,P < 0. 05),tumor control(RR = 1. 64,95% CI: 1. 21-2. 24,P = 0. 002),and pain control(RR = 3. 15,95% CI: 2. 45-4. 05,P < 0. 05). There were no significant differences between the two groups in the incidence rates of leukopenia(RR =1. 05,95% CI: 0. 85-1. 30,P > 0. 05),gastrointestinal reactions(RR = 0. 89,95% CI: 0. 56-1. 42,P > 0. 05),and liver injury(RR = 1. 29,95% CI: 0. 95-1. 75,P > 0. 05). Since the outcome measure of pain control was involved in the highest number of studies,funnel plots were generated and showed no significant risk of bias. Conclusion Compared with gemcitabine alone,HIFU combined with gemcitabine can increase patients' survival rate and improve their symptoms,with a similar incidence rate of adverse effects. Further studies are needed for this combined therapy.
- pancreatic neoplasms /
- high-intensity focused ultrasound ablation /
- gemcitabine /
- Meta-analysis as topic

HTML全文

参考文献(23)

[1] Pancreatic Cancer Committee of Chinese Anti-Cancer Association. Comprehensive guidelines for the diagnosis and treatment of pancreatic cancer(2018 version)[J]. J Clin Hepatol,2018,34(10):2109-2120.(in Chinese)中国抗癌协会胰腺癌专业委员会．胰腺癌综合诊治指南(2018版)[J]．临床肝胆病杂志，2018,34(10):2109-2120.

[2] HIDALGO M. Pancreatic cancer[J]. N Engl J Med,2010,362(17):1605-1617.

[3] SIEGEL R,NAISHADHAM D,JEMAL A. Cancer statistics,2013[J]. CA Cancer J Clin,2013,63(1):11-30.

[4] KAMISAWA T,WOOD LD,ITOI T,et al. Pancreatic cancer[J]. Lancet,2016,388(10039):73-85.

[5] RAHIB L,SMITH BD,AIZENBERG R,et al. Projecting cancer incidence and deaths to 2030:The unexpected burden of thyroid,liver,and pancreas cancers in the United States[J].Cancer Res,2014,74(11):2913-2921.

[6] SQUADRONI M,FAZIO N. Chemotherapy in pancreatic adenocarcinoma[J]. Eur Rev Med Pharmacol Sci,2010,14(4):386-394.

[7] NEOPTOLEMOS JP,STOCKEN DD,BASSI C,et al. Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection:A randomized controlled trial[J]. JAMA,2010,304(10):1073-1081.

[8] PETRELLI F,COINU A,BORGONOVO K,et al. Progression-free survival as surrogate endpoint in advanced pancreatic cancer:Meta-analysis of 30 randomized first-line trials[J].Hepatobiliary Pancreat Dis Int,2015,14(2):124-131.

[9] ZHUO M,CUI JJ,WANG LW. Selection and therapeutic effect evaluation of chemotherapy regimens for pancreatic cancer[J]. J Clin Hepatol,2017,33(1):53-56.(in Chinese)卓萌，崔玖洁，王理伟．胰腺癌化疗方案的选择及疗效评价[J]．临床肝胆病杂志，2017,33(1):53-56.

[10] ZHOU Y. High-intensity focused ultrasound treatment for advanced pancreatic cancer[J]. Gastroenterol Res Pract,2014,2014:205325.

[11] GE HY,MIAO LY,XIONG LL,et al. High-intensity focused ultrasound treatment of late-stage pancreatic body carcinoma:Optimal tumor depth for safe ablation[J]. Ultrasound Med Biol,2014,40(5):947-955.

[12] LEE ES,LEE JY,KIM H,et al. Pulsed high-intensity focused ultrasound enhances apoptosis of pancreatic cancer xenograft with gemcitabine[J]. Ultrasound Med Biol,2013,39(11):1991-2000.

[13] CHOTI MA,DIXON E,TYLER D. Pretreatment assessment of resectable and borderline resectable pancreatic cancer:Expert consensus statement by Callery et al[J]. Ann Surg Oncol,2009,16(7):1734-1735.

[14] LI T,WANG YN,KHOKHLOVA TD,et al. Pulsed high-intensity focused ultrasound enhances delivery of doxorubicin in a preclinical model of pancreatic cancer[J]. Cancer Res,2015,75(18):3738-3746.

[15] ZHANG Y,JI YS,ZHAO H,et al. Clinical outcome assessment of high intensity focused ultrasound ablation for pancreatic cancer in elderly patients[J]. Geriatr Health Care,2013,19(5):308-311.(in Chinese)张宇，吉永烁，赵洪，等．强度聚焦超声治疗老年胰腺癌的疗效观察[J]．老年医学与保健，2013,19(5):308-311.

[16] GAO ZQ,ZHANG G,WU Y,et al. The application of high intensity focused ultrasound combined with the treatment of Gemcitabine for advanced pancreatic cancer[J]. J Hepatol Surg,2018,30(2):98-101.(in Chinese)高志强，张弓，吴阳，等．海扶刀联合吉西他滨在中晚期胰腺癌治疗中的应用[J]．肝胆胰外科杂志，2018,30(2):98-101.

[17] WANG HM,ZHOU DH. High intensity focused ultrasound combined with concurrent gemcitabine chemotherapy in mid-term and advanced pancreatic cancer[J]. Chin J Clin Res,2012,25(7):627-629.(in Chinese)王虎明，周丁华．高强度聚焦超声消融联合同步吉西他滨化疗治疗中晚期胰腺癌[J]．中国临床研究，2012,25(7):627-629.

[18] ZENG QD,LYU LH,ZHANG XG,et al. High intensity focused ultrasound therapy in combination with gemcitabine for advanced pancreatic carcinoma[J]. Chin J Hepatol Surg,2006,12(11):748-750.(in Chinese)曾庆东，吕丽红，张秀国，等．高强度聚焦超声联合健择治疗晚期胰腺癌的临床研究[J]．中华肝胆外科杂志，2006,12(11):748-750.

[19] SHI N,OU SJ,PENG XH. Clinical observation of high intensity focused ultrasound combined with gemcitabine in the treatment of pancreatic neoplasm[J]. Chin Gen Pract,2011,14(14):1597-1599.(in Chinese)史南，欧善际，彭晓晖．高强度聚焦超声联合吉西他滨治疗胰腺癌疗效观察[J]．中国全科医学，2011,14(14):1597-1599.

[20] WANG NY,ZHAO HJ,ZHENG XH,et al. Clinical study of highintensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma[J]. J Clin Hepatol,2011,27(11):1193-1195.(in Chinese)王楠娅，赵恒军，郑晓辉，等．高强度聚焦超声联合吉西他滨治疗不可切除胰腺癌的临床疗效[J]．临床肝胆病杂志，2011,27(11):1193-1195.

[21] YU Y,ZHANG Y,ZHAO H,et al. Therapeutic effect of high intensity focused ultrasound on advanced pancreatic cancer[J]. Chin J Pancreatol,2009,9(3):153-155.(in Chinese)虞阳，张宇，赵洪，等．高能聚焦超声热疗对晚期胰腺癌的疗效观察[J]．中华胰腺病杂志，2009,9(3):153-155.

[22] LV W,YAN T,WANG G,et al. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma[J]. Ther Clin Risk Manag,2016,12:687-691.

[23] NING Z,XIE J,CHEN Q,et al. HIFU is safe,effective,and feasible in pancreatic cancer patients:A monocentric retrospective study among 523 patients[J]. Onco Targets Ther,2019,12(1):1021-1029.

施引文献

资源附件(0)

访问统计